1282513-03-4 Usage
Molecular structure
1H-Pyrazole-1-acetic acid, 4-[5,6-dihydro-2-[3-Methyl-1-(1-Methylethyl)-1H-1,2,4-triazol-5-yl]iMidazo[1,2-d][1,4]benzoxazepin-9-yl]-α,α-diMethylhas a complex molecular structure that includes a pyrazole-1-acetic acid core and a substituted imidazo-benzoxazepin core.
Substitution
The compound is substituted with a 4-[5,6-dihydro-2-[3-Methyl-1-(1-Methylethyl)-1H-1,2,4-triazol-5-yl]iMidazo[1,2-d][1,4]benzoxazepin-9-yl]-α,α-diMethyl group, which contributes to its complex structure and potential pharmacological or biological activities.
Pharmacological or biological activities
Given the presence of the complex substituted imidazo-benzoxazepin core, 1H-Pyrazole-1-acetic acid, 4-[5,6-dihydro-2-[3-Methyl-1-(1-Methylethyl)-1H-1,2,4-triazol-5-yl]iMidazo[1,2-d][1,4]benzoxazepin-9-yl]-α,α-diMethylis likely to exhibit pharmacological or biological activities, although the specific functions and properties would need further investigation.
Experimental studies
To determine the specific functions and properties of 1H-Pyrazole-1-acetic acid, 4-[5,6-dihydro-2-[3-Methyl-1-(1-Methylethyl)-1H-1,2,4-triazol-5-yl]iMidazo[1,2-d][1,4]benzoxazepin-9-yl]-α,α-diMethyl-, experimental studies would be required, as the complex structure and potential activities cannot be predicted solely based on its chemical name or structure.
Potential applications
Due to its complex structure and possible pharmacological or biological activities, 1H-Pyrazole-1-acetic acid, 4-[5,6-dihydro-2-[3-Methyl-1-(1-Methylethyl)-1H-1,2,4-triazol-5-yl]iMidazo[1,2-d][1,4]benzoxazepin-9-yl]-α,α-diMethylmay have potential applications in the development of new drugs or therapeutic agents, although further research would be needed to confirm these possibilities.
Check Digit Verification of cas no
The CAS Registry Mumber 1282513-03-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,8,2,5,1 and 3 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1282513-03:
(9*1)+(8*2)+(7*8)+(6*2)+(5*5)+(4*1)+(3*3)+(2*0)+(1*3)=134
134 % 10 = 4
So 1282513-03-4 is a valid CAS Registry Number.
1282513-03-4Relevant articles and documents
Manufacture of the PI3K β-Sparing Inhibitor Taselisib. Part 2: Development of a Highly Efficient and Regioselective Late-Stage Process
St-Jean, Frédéric,Remarchuk, Travis,Angelaud, Rémy,Carrera, Diane E.,Beaudry, Danial,Malhotra, Sushant,McClory, Andrew,Kumar, Archana,Ohlenbusch, Gerd,Schuster, Andreas M.,Gosselin, Francis
, p. 783 - 793 (2019/04/01)
A highly efficient and regioselective manufacturing route for the phosphoinositide 3-kinase β-sparing inhibitor taselisib was developed. Highlights of the synthesis include: (1) magnesium-mediated formation of a challenging cyclic amidine; (2) regioselect
PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS
-
, (2014/09/29)
Processes are described for the preparation of PI3K inhibitor, GDC-0032, Formula (I), having the structure: Formula (I) (GDC-0032), and intermediates useful for the preparation of (I).
MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE 3 KINASE INHIBITOR COMPOUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
-
, (2014/01/08)
Methods and compositions are provided for treating hyperproliferative disorders in patients with a PI3K inhibitor, GDC-0032 as a single agent or in combination with chemotherapeutic agents.
BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
-
Page/Page column 214, (2011/04/19)
Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
